[{"id":"e4bb6ebb-d0a1-45a9-8623-25eb132314cd","acronym":"POPLAR-NF2","url":"https://clinicaltrials.gov/study/NCT05130866","created_at":"2023-08-24T11:08:27.986Z","updated_at":"2024-07-02T16:35:16.781Z","phase":"Phase 2/3","brief_title":"Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas","source_id_and_acronym":"NCT05130866 - POPLAR-NF2","lead_sponsor":"Recursion Pharmaceuticals Inc.","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e REC-2282"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 06/20/2022","start_date":" 06/20/2022","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-03-01"}]